Olaparib

Olaparib was developed to specifically target PARP, which becomes more critical in cancers that develop as a consequence of an inherited mutation in the DNA-repair genes. Its activity is largely confined to those breast and ovary cancers that have defective BRCA genes on the basis of inheritance. It could similarly be active in other cancers, such as Pancreatic, that are associated with these genetic defects but more data is needed. Olaparib was developed to specifically target PARP, which becomes more critical in cancers that develop as a consequence of an inherited mutation in the DNA-repair genes. Its activity is largely confined to those breast and ovary cancers that have defective BRCA genes on the basis of inheritance. It could similarly be active in other cancers, such as Pancreatic, that are associated with these genetic defects but more data is needed.